Cargando…
Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation
• Molecular testing may play a role in the determination of targeted therapy treatment options. • Targeted therapy provides treatment options for recurrent cervical cancer. • MEK inhibitor is a treatment option for recurrent cervical cancer in a patient with KRAS mutation.
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4434143/ https://www.ncbi.nlm.nih.gov/pubmed/26075998 http://dx.doi.org/10.1016/j.gore.2014.09.003 |